Onconetix (ONCO) Q4 2025 earnings summary

Executive summary

• Commercial-stage biotech focused on men's health and oncology, with Proclarix as the lead product after abandoning ENTADFI due to resource constraints and full asset impairment as of 2025.

• Acquired Proteomedix in December 2023, making Proclarix a wholly owned asset; entered exclusive US commercialization partnership with LabCorp.

• Entered a Share Exchange Agreement in February 2026 to acquire Realbotix, subject to closing conditions and significant dilution for existing shareholders.

• Raised capital through Series D and E PIPE financings in late 2025, but continues to face substantial doubt about ability to continue as a going concern.

Financial highlights

• 2025 revenue was $0.8M, down from $2.5M in 2024, due to the end of a major development services contract; product sales were stable at ~$0.2M.

• Net loss for 2025 was $14.0M, a significant improvement from $58.7M in 2024, driven by lower operating expenses and reduced impairments.

• Gross margin remained positive; cost of revenue fell to $0.2M in 2025 from $1.5M in 2024.

• Operating expenses dropped to $18.5M in 2025 from $57.5M in 2024, reflecting cost reductions and the absence of large impairments seen in 2024.

• Cash at year-end 2025 was $5.2M, with a working capital deficit of $3.1M and accumulated deficit of $131.2M.

Outlook and guidance

• Management expects continued operating losses and negative cash flows, with significant additional capital required to fund operations and commercialize Proclarix.

• Revenue growth is anticipated from Proclarix sales in Europe and, pending regulatory progress, in the US via LabCorp.

• No guidance provided for profitability; substantial doubt remains about ability to continue as a going concern.